Explosive Development of BCMA CAR T-Cell Therapies for Multiple Myeloma
San Diego, CA—A dizzying array of new chimeric antigen receptor (CAR) T-cell therapies targeting the B-cell maturation antigen (BCMA) designed specifically for the treatment of multiple myeloma was presented at ASH 2018. BCMA-targeted CAR T-cell therapies are designed to improve T-cell persistence, depth of response, and tolerability. Response rates reported at ASH 2018 range from 70% to 100%, depending on the patient population and the use of previous regimens.
BCMA is a common myeloma cell-surface protein associated with myeloma cell growth, survival, and proliferation. None of these drugs has so far been approved by the FDA, and they are in various stages of development.
US Front-Runners: bb2121 and Add-On bb21217
bb2121 is considered the front-runner CAR T-cell therapy in multiple myeloma, with the most potential for FDA approval; it has already granted this agent a breakthrough designation status. This agent has a 4-1BB co-stimulatory signaling domain and targets BCMA.
Updates reported from the doseescalation/dose-expansion CRB-401 study showed an objective response rate (ORR) of 95.5% at the highest dose level, median progression-free survival (PFS) of 11.8 months at the highest dose level, and median PFS of 17.7 months in patients with no minimal residual disease (MRD). Overall, 63% of patients had cytokine release syndrome, which was mostly grade 1 or 2.
The 43 patients enrolled in the CRB-401 study were heavily pretreated (with a median of 8 previous therapies), and almost all of them had undergone stem-cell transplant. Updated findings from 194 days of follow-up demonstrated a complete response or stringent complete response rate of 50%, and a very good partial response (VGPR) rate of 36.4%. The median PFS was 11.8 months, and the median duration of response was 10.8 months.
Another CAR T-cell therapy, bb21217, builds on the bb2121 platform and is designed to improve T-cell persistence by including a PI3K inhibitor in the manufacturing process to drive cells toward a memory-like phenotype. Preliminary results were reported from a phase 1 clinical trial on the first 12 patients who received treatment with bb21217.
The ORR at the first dose tested was 83.3%, with a complete response or stringent complete response rate of 25%, and a VGPR or better of 50%. Although almost two-thirds of patients had cytokine release syndrome, all but 1 were grades 1 and 2. Neurotoxicity was reported in 25% of patients.
“Responses are deepening over time. The first patient continues in response more than 1 year later. We saw 100% MRD negativity in 4 of 4 responders; both nonresponders were MRD-positive,” said lead investigator Nina Shah, MD, Hematology and Blood and Marrow Transplant Clinic, University of California, San Francisco.
China’s Lead CAR T-Cell Candidate for Myeloma
China’s lead CAR T-cell candidate for multiple myeloma is LCAR-B38M, which is being developed as JNJ-68284528. Experts believe that this agent may soon enter the US market. LCAR-B38M has 2 domains that target BCMA: a co-stimulatory domain of 4-1BB and a lentivirus vector for transduction.
“This confers high avidity binding and distinguishes LCAR-B38M from other BCMA-targeted therapies,” said lead investigator Wan-Hong Zhao, MD, PhD, Department of Hematology, the Second Affiliated Hospital of Xi’an Jiaotong University, China.
The first-in-human LEGEND-2 clinical trial of bispecific LCAR-B38M CAR T-cell therapy was featured at a press briefing at ASH 2018. In 57 evaluable patients (of the 74 enrolled patients), the ORR was 88%, complete response was 74%, VGPR was 4%, and partial response was 11%. The median duration of response was 16 months, and the median PFS was 15 months. The median overall survival (OS) was not yet reached, and the 12-month median OS was 75%.
Cytokine release syndrome was reported in 90% of the patients (grade 3 in 7%, no grade 4); 1 patient had grade 1 neurotoxicity.
Patients were followed for 12 months; the disease relapsed at a median of 3 previous regimens. “Response was achieved with low CAR T-cell doses. BCMA expression did not correlate with clinical response,” Dr Zhao said.
Additional US CAR T-Cell Therapies
Preliminary studies of 4 different CAR T-cell therapies being explored in multiple myeloma in the United States were presented at the meeting.
MCARH171: Phase 1 Study
Final results of a phase 1 study of 2 different dose levels of MCARH171 in 11 patients showed a 46% VGPR rate, and 2 patients had a partial response. The ORR was 64%, with no complete responses. Overall, 55% of patients had cytokine release syndrome (18% grade 3) and 9% had neurotoxicity.
JCARH125: Phase 1/2 Study
The multicenter, phase 1/2 EVOLVE clinical trial included 44 heavily pretreated patients with refractory multiple myeloma who received treatment with JCARH125 at various dose levels. With short follow-up, the ORR was 82%; the rate of VGPR or better was 48%, and the complete response or stringent complete response rate was 27%. Overall, 80% of patients had cytokine release syndrome, of which 9% was grade ≥3, and 18% had neurologic adverse events, of which 7% were grade ≥3.
“JCARH125 is a BCMA CAR T-cell product, with a fully human binder and optimized manufacturing process that enriches for central memory T-cell phenotype. JCARH125 was highly active in a heavily pretreated relapsed or refractory multiple myeloma patient population with limited follow-up so far,” said Sham Mailankody, MBBS, Medical Oncologist, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York City, who presented these initial proof of concept data. This product is optimized through its design for central memory T-cell phenotype.
FCARH143: Phase 1 Study
A phase 1 study evaluated FCARH143 in 11 patients with multiple myeloma and different levels of BCMA expression. All patients achieved response, with a complete response or stringent complete response rate of 36% and a VGPR rate of 46%. Although 91% of patients had cytokine release syndrome, no grade ≥3 was observed. Only 1 case of neurotoxicity was reported.
Disease relapse occurred in 2 patients: 1 patient with low BCMA levels after 79 days of therapy and 1 patient with high BCMA levels at 180 days of therapy. Both patients were retreated with a lower dose of CAR T-cell therapy.
“BCMA antigen loss may represent a mechanism of resistance. Measures that increase BCMA expression may broaden eligibility and improve responses,” noted Damian J. Green, MD, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
P-BCMA-101: Phase 1 Study
This CAR T-cell therapy is also enriched for greater T-cell memory designed to increase the duration of response and reduce toxicity, according to senior investigator Krina K. Patel, MD, MSc, Assistant Professor, Department of Lymphoma and Myeloma, M.D. Anderson Cancer Center, Houston, TX.
In a phase 1 clinical trial, 21 heavily pretreated patients with relapsed multiple myeloma received treatment with P-BCMA-101 across 5 different dose levels. In 3 patients who received the highest dose, the ORR was 100%, with VGPR or better in 2 (68%) patients. At lower doses, the ORR was almost 70%. Across all patients, cytokine release syndrome was reported in only 9.5% of patients (all grade 1 or 2).
“P-BCMA-101 induces high response rates and deep responses in a heavily pretreated relapsed or refractory multiple myeloma population, with responses still developing. Lack of significant toxicity may allow for greater patient access, such as through administration at community hospitals and/or outpatient sites,” Dr Patel said.